Literature DB >> 9693394

Continuous covariability of dopamine and serotonin metabolites in human cerebrospinal fluid.

T D Geracioti1, P E Keck, N N Ekhator, S A West, D G Baker, K K Hill, A B Bruce, M D Wortman.   

Abstract

BACKGROUND: Experiments in lower animals and humans have demonstrated the existence of functional interactions between serotonin and dopamine in neuronal tissue. However, the relationship between parameters of serotonin and dopamine neuronal activity over time within the central nervous system (CNS) of the individual human has not yet been established.
METHODS: We used continuous cerebrospinal fluid (CSF) sampling over 6 hours to test the hypothesis that the serotonin metabolite 5-hydroxyindoleacetic acid (5-HIAA) and the dopamine metabolite homovanillic acid (HVA) significantly covary in concentration over time. Two groups of normal volunteers (total n = 16) were studied at separate hospitals and CSF was assayed for 5-HIAA and HVA by high-performance liquid chromatography (HPLC). Three subjects underwent repeat CSF-withdrawal procedures after a 6-week interval.
RESULTS: Strong and sustained positive covariability in concentrations of HVA and 5-HIAA was observed in the CSF of individual humans. High intraindividual correlation coefficients were +0.897 and +0.871 in the two normal volunteer groups. The HVA to 5-HIAA concentration ratio in CSF was 2.2 +/- 0.7 with very little variability over intervals ranging from minutes to weeks.
CONCLUSIONS: The balance between CSF dopamine and serotonin metabolite concentrations remains relatively constant over time in healthy humans. Serial measures of CSF dopamine and serotonin metabolites within the same person could be an effective model in which to explore the interrelationships between these systems in various psychiatric syndromes, in response to drug treatment, and during provactive testing.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9693394     DOI: 10.1016/s0006-3223(97)90372-3

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  7 in total

Review 1.  Where Is Dopamine and how do Immune Cells See it?: Dopamine-Mediated Immune Cell Function in Health and Disease.

Authors:  S M Matt; P J Gaskill
Journal:  J Neuroimmune Pharmacol       Date:  2019-05-11       Impact factor: 4.147

2.  Cerebrospinal Fluid Levels of Monoamine Metabolites in the Epileptic Baboon.

Authors:  C Ákos Szabó; Mayuri Patel; Victor V Uteshev
Journal:  J Primatol       Date:  2015-10-14

3.  Neuroendocrine aspects of pediatric aggression: Can hormone measures be clinically useful?

Authors:  Drew H Barzman; Avni Patel; Loretta Sonnier; Jeffrey R Strawn
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-11       Impact factor: 2.570

4.  [Monoaminergic transmitters in the cerebrospinal fluid of patients with acute, chronic, and intermittent pain. Interface between pain and depression?].

Authors:  M Strittmatter; D Ostertag; K H Hoffmann; C Paulus; C Fischer; S Meyer
Journal:  Nervenarzt       Date:  2005-04       Impact factor: 1.214

5.  Non-neurological surgery results in a neurochemical stress response.

Authors:  R Anckarsäter; H Zetterberg; J-E Månsson; K Blennow; H Anckarsäter
Journal:  J Neural Transm (Vienna)       Date:  2008-02-04       Impact factor: 3.575

6.  D-amino acid oxidase activator gene (DAOA) variation affects cerebrospinal fluid homovanillic acid concentrations in healthy Caucasians.

Authors:  Dimitrios Andreou; Peter Saetre; Thomas Werge; Ole A Andreassen; Ingrid Agartz; Göran C Sedvall; Håkan Hall; Lars Terenius; Erik G Jönsson
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-28       Impact factor: 5.270

7.  Kynurenine pathway in post-mortem prefrontal cortex and cerebellum in schizophrenia: relationship with monoamines and symptomatology.

Authors:  Amira Ben Afia; Èlia Vila; Belén Ramos; Borja Garcia-Bueno; Karina S MacDowell; Aida Ormazabal; Juan C Leza; Josep M Haro; Rafael Artuch
Journal:  J Neuroinflammation       Date:  2021-09-12       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.